Study of Serum Betatrophin Level in The Patients of Type 2 Diabetes Mellitus

Abstract

Background: Type 2 DM is due primarily to lifestyle and genetic factors. A number of lifestyle factors are known to be important to the development of type 2 DM. Betatrophin, also known as angiopoietin-like protein (ANGPTL8), is a circulating protein predominantly produced in the liver and adipose tissue. Betatrophin is induced as a result of insulin resistance. It is reported to modulate pancreatic β-cell mass and glucose homeostasis reflectable on lipid metabolism. Aim of the Study: Evaluation of the role of betatrophin in patients with type 2 diabetes mellitus. Patients and Methods: This clinical study was carried out at Clinical Pathology Department, Tanta University Hospital and included 80 subjects who were divided into two groups: Group 1:40 Patients diagnosed with type 2 diabetes mellitus. Group 2: 40 normal subjects with matched age and sex as a control group. Results: In type 2 diabetes mellitus patients group, serum betatrophin ranged from 25.83 to 860.65 ng/l with a median value of 54.815 ng/l while in control group, betatrophin ranged from 7.5-53.2 ng/l with a madian value of 11.250 ng/l. There was significant statistical difference in betatrophin between the two groups. (P < 0.001). Betatrophin was significantly higher in type 2 diabtes mellitus patients as compared to control group. Conclusion: Circulating betatrophine concentrations were significantly increased in patients with T2 DM and associated with glucose homeostasis and insulin sensitivity. Thus, the level of serum betatrophin has a potential role in detection and pathogenesis of T2DM.